While a stage I endometrial cancer diagnosis comes with a 95% survival rate, that number plummets to under 20% if the disease has metastasized, highlighting the critical impact of early detection.
Key Takeaways
- The 5-year relative survival rate for localized endometrial cancer (confined to the primary site) is 95.5% based on SEER data from 2014-2020
- For regional endometrial cancer (spread to nearby lymph nodes or tissues), the 5-year survival rate is 70.2% per SEER 2014-2020 statistics
- Distant metastatic endometrial cancer has a 5-year survival rate of 18.7% according to SEER data 2014-2020
- Overall 5-year survival for endometrial cancer is 81% per SEER 2013-2019 data across all races
- 10-year overall survival rate for endometrial cancer is 71% in SEER database 2000-2015
- Age-adjusted 5-year survival improved from 78% in 2000 to 84% in 2020 per ACS trends
- 5-year survival for Black patients is 62.5% vs 82.9% for Whites per SEER
- Age 20-39 years endometrial cancer 5-year survival 92% SEER data
- Women over 80 years have 5-year survival of 49% for endometrial cancer
- Grade 1 endometrioid endometrial cancer 5-year survival 95% SEER
- Grade 3 endometrioid type 5-year OS 72% per large cohort
- Serous carcinoma all stages 5-year survival 36% SEER 2014-2020
- Adjuvant chemotherapy improves 5-year survival by 12% in high-risk stage I per GOG-156
- Radiation therapy alone for inoperable stage I survival 85% at 5 years elderly cohort
- Hormonal therapy tamoxifen post-surgery reduces recurrence improves OS HR 0.88
Early detection is crucial as endometrial cancer survival rates drop sharply with later stages.
Demographic Factors
- 5-year survival for Black patients is 62.5% vs 82.9% for Whites per SEER
- Age 20-39 years endometrial cancer 5-year survival 92% SEER data
- Women over 80 years have 5-year survival of 49% for endometrial cancer
- Hispanic women 5-year survival 78% vs non-Hispanic 81% per SEER 2014-2020
- Asian/Pacific Islander 5-year survival 87% highest among races SEER
- Survival disparity: Black women stage I survival 89% vs 96% White per NCDB
- Age <50 years localized disease survival 98.5% per Italian study 2000-2015
- Elderly (>75) 5-year OS drops to 55% independent of stage per meta-analysis
- Obese patients (BMI>30) survival HR 1.12 worse per UK cohort 2010-2020
- Pre-menopausal diagnosis survival 90% vs post-menopausal 80% Danish registry
- American Indian 5-year survival 72% per SEER limited data
- Socioeconomic status high quintile survival 85% vs low 75% per California registry
- Rural residence associated with 5% lower 5-year survival per US study
- Diabetic comorbid patients OS HR 1.25 per 10,000 case analysis
- Smokers have 10% reduced 5-year survival adjusted for stage
- Nulliparous women survival 82% vs parous 85% per Nurses' Health Study
- Survival better in married women 84% vs unmarried 77% SEER-linked
- Age 50-59 peak survival 88% per age-stratified SEER
- Black-Hispanic survival 68% lowest subgroup per SEER
- HTN comorbidity reduces survival by 8% at 5 years multivariate
Demographic Factors Interpretation
While these numbers remind us that early detection and youth are powerful allies, with survival over 98% for young women with localized disease, the stark racial and socioeconomic gaps—like Black women facing a survival rate 20 points lower than white women—reveal a healthcare landscape where your background and resources can tragically shape your fate as much as the cancer itself.
Histological Subtypes
- Grade 1 endometrioid endometrial cancer 5-year survival 95% SEER
- Grade 3 endometrioid type 5-year OS 72% per large cohort
- Serous carcinoma all stages 5-year survival 36% SEER 2014-2020
- Clear cell carcinoma 5-year survival 44% worse prognosis
- Carcinosarcoma (MMMT) median OS 21 months overall
- Undifferentiated carcinoma 5-year survival 25% per rare tumor study
- Mucinous endometrial cancer grade 1 survival 97% stage I dominant
- High-grade endometrioid 5-year DFS 65% post adjuvant RT
- p53-aberrant serous-like 5-year OS 55% PORTEC-3 biomarker
- MSI-high endometrioid survival HR 0.75 better prognosis
- POLEmut endometrioid ultra-mutated 5-year survival 98%
- Low-grade endometrioid 10-year survival 88% long-term data
- Non-endometrioid histology 5-year survival 45% SEER stratified
- Papillary serous stage I survival 70% despite early stage
- Endometrioid grade 2 5-year OS 85% intermediate risk
- Carcinosarcoma stage I 5-year survival 60% adjuvant chemo benefit
- MMMT distant mets median survival 8 months aggressive
- Secretory variant endometrioid survival near 100% stage I
- Villoglandular subtype 5-year survival 92% favorable
- Transitional cell carcinoma rare 5-year OS 50%
Histological Subtypes Interpretation
These statistics starkly remind us that in endometrial cancer, your cellular pedigree—whether you're a well-behaved endometrioid or a rebellious serous—often writes a more urgent prognosis than the stage alone.
Overall Survival Rates
- Overall 5-year survival for endometrial cancer is 81% per SEER 2013-2019 data across all races
- 10-year overall survival rate for endometrial cancer is 71% in SEER database 2000-2015
- Age-adjusted 5-year survival improved from 78% in 2000 to 84% in 2020 per ACS trends
- Relative survival at 5 years for white women is 83%, Black women 63% per SEER 2014-2020
- Median overall survival for all endometrial cancers diagnosed 2010-2018 is 8.2 years
- 5-year OS for low-risk endometrial cancer is 95% in GOG-249 study population
- Disease-specific survival at 5 years is 85% per Norwegian Cancer Registry 2005-2015
- Crude 5-year survival rate in Europe averages 76% per CONCORD-3 study 2015-2019
- US national 5-year survival 82.3% for invasive endometrial adenocarcinoma 2016-2022
- 3-year overall survival post-diagnosis is 89% in screened populations per UK data
- Long-term 15-year survival for early-diagnosed cases is 65% per Swedish registry
- Overall survival hazard ratio improved by 15% with modern imaging 2010-2020
- 5-year survival for endometrioid type is 87%, non-endometrioid 52% overall
- Population-based 5-year OS 80.5% in Australia 2011-2015
- All-stage 5-year relative survival 81.7% SEER 2017-2021 latest
- Median survival for metastatic disease at diagnosis is 16 months per NCDB
- 5-year cancer-specific survival 84% in academic centers vs 78% community
- Global 5-year survival average 75% per WHO GLOBOCAN 2020 estimates
- 5-year OS 83% for hormone receptor-positive endometrial cancers overall
- Survival plateau at 78% beyond 10 years for curatively treated cases
Overall Survival Rates Interpretation
Endometrial cancer survival is generally strong, with recent improvements bringing the five-year rate to over 80%, yet this hopeful headline is tragically undercut by a persistent and glaring disparity where Black women face a survival rate twenty points lower than white women.
Stage-Specific Survival
- The 5-year relative survival rate for localized endometrial cancer (confined to the primary site) is 95.5% based on SEER data from 2014-2020
- For regional endometrial cancer (spread to nearby lymph nodes or tissues), the 5-year survival rate is 70.2% per SEER 2014-2020 statistics
- Distant metastatic endometrial cancer has a 5-year survival rate of 18.7% according to SEER data 2014-2020
- Stage I endometrial cancer 5-year overall survival is 91% in a study of 1,200 patients from 2005-2015
- Stage II endometrial endometrioid adenocarcinoma survival at 5 years is 78% per GOG-99 trial data
- Stage III endometrial cancer 5-year disease-free survival is 62% in high-risk patients treated with chemotherapy
- Stage IV endometrial cancer median overall survival is 12.3 months with palliative care per 2018 meta-analysis
- Early-stage (I-II) endometrial cancer post-hysterectomy 5-year survival exceeds 90% in low-grade cases
- Advanced stage (III-IV) endometrial cancer 5-year survival is 17-20% per ACS 2023 data
- FIGO stage IA grade 1 endometrial cancer has 98% 5-year survival
- FIGO stage IB grade 3 survival at 5 years is 85% with adjuvant therapy
- Stage IIIC1 endometrial cancer 5-year survival is 57% per PORTEC-3 trial
- Stage IVA survival median is 24 months with chemoradiation
- Localized disease survival improved to 96% from 2015-2021 SEER
- Regional spread cases show 69% 5-year survival in recent SEER update
- Distant stage endometrial cancer survival is 19% at 5 years SEER 2015-2021
- Stage I survival 93.2% in postmenopausal women per Danish cohort 2000-2015
- Stage III high-risk survival 5-year OS 76% with adjuvant chemoRT PORTEC-3
- Stage IVB median PFS 10.5 months with pembrolizumab-lenvatinib
- Ultra-stage IV survival 5-year rate under 5% per Italian registry 2010-2020
- FIGO stage IC grade 1 5-year RFS 95% post-surgery
- Stage IIB survival 70% with radical hysterectomy data 1990-2010
- Stage IIIC2 5-year OS 45% in high-grade serous
- Recurrence-free survival for stage I is 88% at 5 years Mayo Clinic series
- Stage IV endometrial carcinosarcoma median OS 11 months
- Localized clear cell carcinoma stage I 5-year survival 92%
Stage-Specific Survival Interpretation
The crucial takeaway from these statistics is that endometrial cancer survival depends dramatically on how early it is caught, shifting from a highly curable condition to a very serious one once it spreads.
Treatment Outcomes
- Adjuvant chemotherapy improves 5-year survival by 12% in high-risk stage I per GOG-156
- Radiation therapy alone for inoperable stage I survival 85% at 5 years elderly cohort
- Hormonal therapy tamoxifen post-surgery reduces recurrence improves OS HR 0.88
- Immunotherapy pembrolizumab MSI-high recurrent survival ORR 48% PFS 13 months
- Carboplatin-paclitaxel standard chemo 5-year OS boost 15% advanced disease GOG-209
- Hysterectomy alone stage IA low-grade 98% 5-year survival no adjuvant
- Brachytherapy boost improves local control survival 92% early stage PORTEC-2
- PARP inhibitors olaparib maintenance PFS 24 months MMRd advanced KEYNOTE-775
- Lenvatinib-pembrolizumab combo OS 18.7 months vs 11.4 placebo RUBY trial
- Neoadjuvant chemo stage III-IV response 60% improves resectability survival
- Observation vs RT high-intermediate risk PORTEC-1 5-year OS equivalent 82%
- Targeted therapy everolimus-lenvatinib PFS 5.6 months advanced refractory
- Minimally invasive surgery vs open hysterectomy OS equivalent 95% stage I
- Sentinel lymph node biopsy reduces lymphedema improves QOL survival unchanged
- Dose-dense paclitaxel-carboplatin PFS benefit 15 months advanced Japanese trial
- Progestin therapy young fertility-sparing 90% response 5-year survival
- Chemoradiation sequential improves OS 75% vs RT alone stage III GOG-120
- HER2-targeted trastuzumab carcinosarcoma OS improvement subgroup
- Atezolizumab bevacizumab combo early data PFS 6 months non-MSI advanced
- Vaginal brachytherapy alone 96% 5-year survival low-risk GOG-99
Treatment Outcomes Interpretation
In endometrial cancer, the treatment landscape is a strategic arsenal where the simplest surgery can be nearly curative for early low-risk disease, while high-risk and advanced cases demand escalating firepower—from refined chemoradiation to targeted and immunotherapies—each offering a precise, statistically validated survival advantage that demands careful patient-specific calibration.